Frailty, polypharmacy and deprescribing.

@article{2016FrailtyPA,
  title={Frailty, polypharmacy and deprescribing.},
  author={},
  journal={Drug and therapeutics bulletin},
  year={2016},
  volume={54 6},
  pages={69-72}
}
Multimorbidity and associated polypharmacy present a significant and increasing challenge to patients, carers and healthcare professionals.(1,2) While it is recognised that polypharmacy can be beneficial, there is considerable potential for harm, particularly through drug interactions, adverse drug events and non-adherence.(1) Such harms are amplified in… CONTINUE READING